Please assess the completion status of the following clinical trial:

Trial Title: A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult~* Recovering of written and dated informed consent form~* Social Security medical cover~* Left Iliac Fossa (LIF) pain~* Moderate fever (\>37.8°C)~* Sensitivity/defence during LIF palpation~Biological results :~* CRP \> 10mg/L~* NFS \> 10G/L~* Neutrophil Granulocytosis \> 75%~* Radiological results - presence to the scan :diverticul \& pericolic infiltration~Exclusion Criteria:~* Patients treated by antibiotherapy in the last 15 days prior inclusion~* Patients treated by morphinic drug~* Patients treated by anticoagulant drug~* Pregnant or breast-feeding women~* Patients presenting allergy to active principal, to galactose~* Patients having taking part in another study in the last 3 months prior inclusion~* Patients unable to comply with the study requirements~* Patients presenting Chronic affection inconsistent with the study~* Patients presenting high fever~* Patients presenting abdominal contracture~* Patients presenting immunosuppression~* Radiological sign of complication (abscess\>3cm)~* Patients presenting Pathology inconsistent with efficacy evaluatio

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Secnidazol-Ciprofloxacin (Type: EXPERIMENTAL): 2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
- Amoxicillin-Clavulanic Acid (Type: ACTIVE_COMPARATOR): 3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).